What is HC Wainwright's Estimate for ANRO Q1 Earnings?

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for Alto Neuroscience in a report issued on Monday, April 7th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.45) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. HC Wainwright also issued estimates for Alto Neuroscience's Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.32) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($3.04) EPS, FY2027 earnings at ($3.07) EPS, FY2028 earnings at ($2.99) EPS and FY2029 earnings at ($1.69) EPS.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.09.

Separately, William Blair reiterated an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of "Moderate Buy" and an average target price of $15.40.

Alto Neuroscience Stock Up 4.8 %

NYSE:ANRO traded up $0.10 during mid-day trading on Thursday, hitting $2.18. The stock had a trading volume of 125,558 shares, compared to its average volume of 372,050. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $17.55. The stock has a 50-day simple moving average of $2.83 and a two-hundred day simple moving average of $4.72. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $59.02 million, a PE ratio of -0.86 and a beta of 2.16.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ANRO. Wells Fargo & Company MN lifted its holdings in shares of Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock worth $46,000 after purchasing an additional 3,139 shares during the period. Deutsche Bank AG boosted its holdings in shares of Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock valued at $64,000 after acquiring an additional 3,629 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Alto Neuroscience by 619.2% during the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company's stock worth $49,000 after acquiring an additional 3,715 shares during the period. Rhumbline Advisers raised its holdings in Alto Neuroscience by 24.4% during the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock worth $108,000 after purchasing an additional 5,008 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Alto Neuroscience by 15.0% in the fourth quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company's stock valued at $221,000 after purchasing an additional 6,812 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.